SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3559 104 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2332Surprised SP didn't drop more after this release...Felix B-3/1/2018
2331'mysterious" IOI clasters blamed on (particle????) syringes in Eylea kiMiljenko Zuanic13/1/2018
2330medpagetoday.com One prediction that ODYSSEY outcome will fail in primary analyMiljenko Zuanic-3/1/2018
2329RE: IO/IO eurekalert.org Where is REGN bi-specific/three-specific fusion proteMiljenko Zuanic-2/26/2018
2328RE: Dupi Many analysts are predicting (speculate) that next growth driver in DupMiljenko Zuanic-2/26/2018
2327REGN should take active part here: nih.govMiljenko Zuanic12/23/2018
2326My guess would be PD-L1 positive (>1%), to close mimic K-189 trial (regardleMiljenko Zuanic-2/22/2018
2325...they are planing NSCLC trial against Keytruda? Slide #28 says, ">= PDDewDiligence_on_SI-2/22/2018
2324Seams they are serious about anti-CTLA-4: clinicaltrials.gov Also, they are plaMiljenko Zuanic-2/22/2018
2323Fusion proteins are undoubtedly harder to reverse engineer; however, MNTA is worDewDiligence_on_SI-2/22/2018
2322Thanks Ian. Abstract is irrelevant, presentation (poster) may help evaluate canMiljenko Zuanic-2/21/2018
2321Link works but you have to copy and paste the last half of it. SI isn't proIan@SI12/21/2018
2320Link doesn't workFelix B-2/21/2018
2319Curious on their attempt to make a fusion "trap" protein rather than aFelix B-2/21/2018
2318From AACR18: REGN4659 (Anti-CTLA-4 Ab in CTLA-4 knock-in mice) abstractsonline.cMiljenko Zuanic-2/21/2018
2317Thanks. From the recent report on Eylea safety, it is obvious that manufacturingMiljenko Zuanic-2/21/2018
2316MNTA/MYL's M710 phase-3 trial will be head-to-head vs Eylea in DME. Results DewDiligence_on_SI-2/21/2018
2315And, there is new problem, surfacing now is bit odd: finance.yahoo.com <RegeMiljenko Zuanic-2/21/2018
2314I don't see any factual discrepancy. "Completion" in a clinicaltriDewDiligence_on_SI-2/19/2018
2313I do not know. IF it is signed as "completed", at least all data colleMiljenko Zuanic-2/19/2018
2312A naive question on my end perhaps, but can the study be complete and not yet unFelix B-2/19/2018
2311At least REGN has a partnered program in IL33 although only in P1 and surprised Felix B-2/19/2018
2310ttps://www.clinicaltrials.gov/ct2/show/NCT01663402?term=praluent+and+outcome&Miljenko Zuanic-2/19/2018
2309What excuse they will find this time? Oh yes, they didn't develop Abs with hMiljenko Zuanic-2/17/2018
2308<I am still not as pessimistic as you are though lol...> In bio sphere anMiljenko Zuanic-2/15/2018
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News